Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era



Rating:

Share or cite this content

Citations should be made in the following way:
K. Crothers (Seattle, United States of America). Antimicrobial resistance and new therapeutic options. Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era

Member's Comments

No comment yet.

Related content which might interest you: Reversing glucocorticoid resistance as a new therapeutic strategy Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Prescribing and guidelines: both must improve to combat antimicrobial resistance Source: Eur Respir J 2012; 39: 1050 Year: 2012 Prescribing and guidelines: both must improve to combat antimicrobial resistance Source: Eur Respir J 2011; 37: 9-11 Year: 2011 Antibiotic management and resistance Source: Eur Respir Monogr 2018; 81: 312-330 Year: 2018 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Better diagnostics for targeted antibiotic therapy Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Biomarkers and rapid diagnostics in antibiotic stewardship Source: International Congress 2015 – PG14 Antibiotic stewardship for respiratory infections Year: 2015 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 How to link antimicrobial and diagnostic stewardship Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006